Baseline characteristics of the study population
| Characteristic . | n (%) or median [range] . |
|---|---|
| Age, y | 46 [20-70] |
| ≥60 y | 4 (18) |
| ALL subtype | |
| T-cell ALL | 4 (18) |
| B-cell ALL | 18 (82) |
| Ph-like | 3/18 (33) |
| Isolated extramedullary disease | 4 (18) |
| Baseline blood parameters | |
| White blood cells (×109/L) | 3.6 [0.1-19.5] |
| Hemoglobin (g/dL) | 9.4 [7.8-12.4] |
| Platelets (×109/L) | 32 [9-257] |
| Bone marrow blasts (%) | 60 [0-87] |
| Cytogenetics | 7/22 (32) |
| Diploid | 3/22 (14) |
| Complex | 3/22 (14) |
| Triploid t(4;11) | 1/22 (4) |
| Miscellaneous | 3/22 (14) |
| Insufficient metaphases/not done | 5/22 (23) |
| TP53 mutation | 5/22 (23) |
| Median prior lines of therapy | 2 [1-6] |
| B-cell ALL | 3 [1-6] |
| Prior INO | 7/18 (39) |
| Prior blinatumomab | 16/18 (89) |
| Prior INO and blinatumomab | 7/18 (39) |
| Prior CD19 CAR T cells | 3/18 (17) |
| Prior allo-SCT | 12/18 (67) |
| T-ALL | 1 [1-3] |
| Prior nelarabine | 1/4 (25) |
| Prior allo-SCT | 1/4 (25) |
| Characteristic . | n (%) or median [range] . |
|---|---|
| Age, y | 46 [20-70] |
| ≥60 y | 4 (18) |
| ALL subtype | |
| T-cell ALL | 4 (18) |
| B-cell ALL | 18 (82) |
| Ph-like | 3/18 (33) |
| Isolated extramedullary disease | 4 (18) |
| Baseline blood parameters | |
| White blood cells (×109/L) | 3.6 [0.1-19.5] |
| Hemoglobin (g/dL) | 9.4 [7.8-12.4] |
| Platelets (×109/L) | 32 [9-257] |
| Bone marrow blasts (%) | 60 [0-87] |
| Cytogenetics | 7/22 (32) |
| Diploid | 3/22 (14) |
| Complex | 3/22 (14) |
| Triploid t(4;11) | 1/22 (4) |
| Miscellaneous | 3/22 (14) |
| Insufficient metaphases/not done | 5/22 (23) |
| TP53 mutation | 5/22 (23) |
| Median prior lines of therapy | 2 [1-6] |
| B-cell ALL | 3 [1-6] |
| Prior INO | 7/18 (39) |
| Prior blinatumomab | 16/18 (89) |
| Prior INO and blinatumomab | 7/18 (39) |
| Prior CD19 CAR T cells | 3/18 (17) |
| Prior allo-SCT | 12/18 (67) |
| T-ALL | 1 [1-3] |
| Prior nelarabine | 1/4 (25) |
| Prior allo-SCT | 1/4 (25) |
Ph-like, Philadelphia like.